12/3/2024

Janusmed kön och genus

Janusmed kön och genus – mykofenolsyra

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C! C!
C! C!

Mykofenolsyra

Mykofenolsyra

Klass : C!

Visa all info

Skriv ut

Kontakta oss

  1. Cellcept (mycophenolate mofetil). DailyMed [www]. US National Library of Medicine. [updated 2019-03-14, cited 2019-07-30].

  2. Myfortic (mycophenolate acid). DailyMed [www]. US National Library of Medicine. [updated 2018-11-03, cited 2019-07-30].

  3. Meaney CJ, Sudchada P, Consiglio JD, Wilding GE, Cooper LM, Venuto RC et al. Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant. J Clin Pharmacol. 2019;59(10):1351-1365.

  4. Momper JD, Misel ML, McKay DB. Sex differences in transplantation. Transplant Rev (Orlando). 2017;31(3):145-150.

  5. Venuto RC, Meaney CJ, Chang S, Leca N, Consiglio JD, Wilding GE et al. Association of Extrarenal Adverse Effects of Posttransplant Immunosuppression With Sex and ABCB1 Haplotypes. Medicine (Baltimore). 2015;94(37):e1315.

  6. Tornatore KM, Meaney CJ, Wilding GE, Chang SS, Gundroo A, Cooper LM et al. Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients. Clin Pharmacokinet. 2015;54(4):423-34.

  7. Pescovitz MD, Guasch A, Gaston R, Rajagopalan P, Tomlanovich S, Weinstein S et al. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am J Transplant. 2003;3(12):1581-6.

  8. Clinical Pharmacology and Biopharmaceutics Review - Cellcept (mycophenolate mofetil). Drugs@FDA [www]. US Food and Drug Administration (FDA). [updated 2000-12-19, cited 2019-07-30].

  9. Meier-Kriesche HU, Ojo AO, Leavey SF, Hanson JA, Leichtman AB, Magee JC et al. Gender differences in the risk for chronic renal allograft failure. Transplantation. 2001;71(3):429-32.

  10. US Food and Drug Administration (FDA). Medical Review - Cellcept (mycophenolate mofetil). Drugs@FDA [www]. [updated 2000-12-20, cited 2019-07-30].

  11. US Food and Drug Administration (FDA). Medical Review - Cellcept (mycophenolate mofetil). Drugs@FDA [www]. [updated 2000-12-20, cited 2019-07-30].

  12. European Medicines Agency (EMA). Cellcept (mycophenoalte mofetil) EPAR - Scientific Discussion. EMA [www]. [updated 2006-04-05, cited 2019-07-30].

  13. Spasić A, Catić-Đorđević A, Veličković-Radovanović R, Stefanović N, Džodić P, Cvetković T. Adverse effects of mycophenolic acid in renal transplant recipients: gender differences. Int J Clin Pharm. 2019;41(3):776-784.

  14. Myfortic (mycophenolate acid). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2019-04-16, cited 2019-07-30]

  15. European Medicines Agency (EMA). EMA recommends additional measures to prevent use of mycophenolate in pregnancy. EMA [www]. [updated 2015-10-24, cited 2019-09-11].

  16. Kuypers DR, Van Mieghem T, Meijers B, Claes K. Updated Manufacturer and European Medicines Agency Recommendations on the Use of Mycophenolate Acid: Balancing the Risks for Male Allograft Recipients. Transplantation. 2016;100(9):e50-1.

  17. Midtvedt K, Åsberg A. Mycophenolate Acid and Balancing the Risk for Male Allograft Recipients. Transplantation. 2017;101(1):e39.

  18. Cellcept (mycophenolate mofetil). Summary of Product Characteristics. European Medicines Agency (EMA). [updated 2018-08-31, cited 2019-09-11].

  19. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-10-29.]

  1. Cellcept (mycophenolate mofetil). DailyMed [www]. US National Library of Medicine. [updated 2019-03-14, cited 2019-07-30].
  2. Myfortic (mycophenolate acid). DailyMed [www]. US National Library of Medicine. [updated 2018-11-03, cited 2019-07-30].
  3. Meaney CJ, Sudchada P, Consiglio JD, Wilding GE, Cooper LM, Venuto RC et al. Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant. J Clin Pharmacol. 2019;59(10):1351-1365.
  4. Momper JD, Misel ML, McKay DB. Sex differences in transplantation. Transplant Rev (Orlando). 2017;31(3):145-150.
  5. Venuto RC, Meaney CJ, Chang S, Leca N, Consiglio JD, Wilding GE et al. Association of Extrarenal Adverse Effects of Posttransplant Immunosuppression With Sex and ABCB1 Haplotypes. Medicine (Baltimore). 2015;94(37):e1315.
  6. Tornatore KM, Meaney CJ, Wilding GE, Chang SS, Gundroo A, Cooper LM et al. Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients. Clin Pharmacokinet. 2015;54(4):423-34.
  7. Pescovitz MD, Guasch A, Gaston R, Rajagopalan P, Tomlanovich S, Weinstein S et al. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am J Transplant. 2003;3(12):1581-6.
  8. Clinical Pharmacology and Biopharmaceutics Review - Cellcept (mycophenolate mofetil). Drugs@FDA [www]. US Food and Drug Administration (FDA). [updated 2000-12-19, cited 2019-07-30].
  9. Meier-Kriesche HU, Ojo AO, Leavey SF, Hanson JA, Leichtman AB, Magee JC et al. Gender differences in the risk for chronic renal allograft failure. Transplantation. 2001;71(3):429-32.
  10. US Food and Drug Administration (FDA). Medical Review - Cellcept (mycophenolate mofetil). Drugs@FDA [www]. [updated 2000-12-20, cited 2019-07-30].
  11. US Food and Drug Administration (FDA). Medical Review - Cellcept (mycophenolate mofetil). Drugs@FDA [www]. [updated 2000-12-20, cited 2019-07-30].
  12. European Medicines Agency (EMA). Cellcept (mycophenoalte mofetil) EPAR - Scientific Discussion. EMA [www]. [updated 2006-04-05, cited 2019-07-30].
  13. Spasić A, Catić-Đorđević A, Veličković-Radovanović R, Stefanović N, Džodić P, Cvetković T. Adverse effects of mycophenolic acid in renal transplant recipients: gender differences. Int J Clin Pharm. 2019;41(3):776-784.
  14. Myfortic (mycophenolate acid). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2019-04-16, cited 2019-07-30]
  15. European Medicines Agency (EMA). EMA recommends additional measures to prevent use of mycophenolate in pregnancy. EMA [www]. [updated 2015-10-24, cited 2019-09-11].
  16. Kuypers DR, Van Mieghem T, Meijers B, Claes K. Updated Manufacturer and European Medicines Agency Recommendations on the Use of Mycophenolate Acid: Balancing the Risks for Male Allograft Recipients. Transplantation. 2016;100(9):e50-1.
  17. Midtvedt K, Åsberg A. Mycophenolate Acid and Balancing the Risk for Male Allograft Recipients. Transplantation. 2017;101(1):e39.
  18. Cellcept (mycophenolate mofetil). Summary of Product Characteristics. European Medicines Agency (EMA). [updated 2018-08-31, cited 2019-09-11].
  19. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-10-29.]